Progressive Multifocal Leukoencephalopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Progressive Multifocal Leukoencephalopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by polyomavirus, also known as JC (John Cunningham) virus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JC virus and an altered or weakened immune system, and genetic or environmental factors.
The Progressive Multifocal Leukoencephalopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Progressive Multifocal Leukoencephalopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Progressive Multifocal Leukoencephalopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Progressive Multifocal Leukoencephalopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Progressive Multifocal Leukoencephalopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Belyntic GmbHBiological E Ltd
Cellevolve Bio
Evrys Bio
Excision BioTherapeutics Inc
Inhibikase Therapeutics Inc
Merck & Co Inc
NeoImmuneTech Inc
Neurimmune Holding AG
Pomona Ricerca SRL
Vir Biotechnology Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Progressive Multifocal Leukoencephalopathy reports